

Ivermectin's Success in Battling COVID-19

By <u>David Heller</u>

Region: <u>USA</u>

Global Research, June 30, 2021

Theme: Science and Medicine

America's Frontline Doctors 27 June 2021

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at <a>ocrg_globalresearch.

A recently <u>published study</u> in this month's American Journal of Therapeutics, took an indepth look at 18 randomized controlled studies on the use of Ivermectin to control COVID-19. The study concludes that the use of Ivermectin "significantly reduced risks of contracting COVID-19" and "found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance."

Ivermectin was first developed as a veterinary drug in the 1970s, however since 1988 it has been prescribed for humans to combat various parasitic infections. Was later added to the WHO's list of <u>essential medications</u> and in 2015 the inventors were <u>awarded the Nobel Prize</u> in Medicine.

With the outbreak of COVID-19, many doctors and scientists were looking for new ways to deal with the virus. At the same time, an interesting series of events occurred one nursing home in Toronto, in February 2020 (just before COVID-19 emerged in Canada the Valley View Nursing Home in Toronto, Canada had a parasitic outbreak. 170 patients at the home were given Ivermectin. The residents of the 4th floor, where the outbreak occurred, were given the highest dose; the rest of the residents were given a prophylactic dose. The staff were not given Ivermectin. Then they had a Covid-19 outbreak. The staff were infected with COVID-19 much more than the patients. Only 6 patients contracted COVID, and they all had mild cases. The patients on the 4th floor, who received the highest dose of ivermectin, had no cases of COVID. These patients were very elderly with comorbidities, and they had much contact with the staff yet only 6% were infected.

Since then, over 60 clinical trials (31 randomized controlled) conducted by 549 scientists in 18,931 patients were conducted to see what if any link Ivermectin has with preventing and treating COVID-19. The conclusions of these studies reveal dramatic positive outcomes for the use of Ivermectin. When used prophylactically patients saw an 85% reduction in hospitalization and death, early treatment was effective 76%, and even when used as a later stage treatment was effective 46% of the time.

While these studies suggested that Ivermectin was indeed a safe, cheap, and effective treatment for COVID-19, many public health policy makers refused to permit its use to treat and prevent COVID-19. The FDA in it's <u>statement</u> said that the "FDA has not approved

ivermectin for use in treating or preventing COVID-19" later explaining that "The FDA has not reviewed data to support use of ivermectin in COVID-19 patients to treat or to prevent COVID-19". Many are insisting it's time for the FDA to review the data and formally approve its use.

One such advocate for the use of Ivermectin is **Dr. Pierre Kory**, a founder of Front Line COVID-19 Critical Care Alliance (FLCCC). Kory, along with the other professionals at the FLCCC developed the specific protocol to prevent and treat COVID-19 using Ivermectin. While the treatment was shunned by the medical establishment and the social media banned promoting or debating the treatment, physicians, like Kory, persisted and advocated for its use. In December 2020 Dr. Kory and others gave an impassioned plea, backed by scientific research at a committee hearing in the U.S. Senate. Stating that Ivermectin "basically obliterates transmission of this virus," the doctor continued saying "When I say miracle I do not use that term lightly[.] ... [T]hat is a scientific recommendation based on mountains of data that has emerged in the last three months."

Unfortunately, many are still uninformed of this treatment, and the <u>medical establishment</u> is still blocking its use. Several hospitals around the country are even refusing to administer the treatment to seriously ill patients. A number of patients had to go as far as to <u>get a court order to force the hospital</u> to permit them to use this life saving medication. Thankfully all of those patients received their Ivermectin and made dramatic turnarounds and subsequently recovered for COVID-19.

The hope of a safe and effective medication to prevent and treat COVID-19 appears to have been found in Ivermectin; unfortunately it continues to be deemed unacceptable by the medical establishment and undiscussable by social media.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from iStock

The original source of this article is <u>America's Frontline Doctors</u> Copyright © <u>David Heller</u>, <u>America's Frontline Doctors</u>, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: **David Heller**

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants

permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca